The relationsphip between apolipoprotein (apo) E phenotypes and the levels of plasma lipid, lipoprotein and apo E in young (mean, 21 years of age) and middle-aged (mean, 49 years of age) subjects was investigated. Apo E phenotypes were determined by a rapid flat gel isoelectric focusing method that we had developed previously. Young subjects with apo E3/2 and E4/3 had significantly higher levels of plasma triglyceride (TG), very low density lipoprotein (VLDL)-TG and VLDL-cholesterol than those with apo E3/3. Middle-aged subjects with apo E3/2 (54.5%) and E4/3 (39.1%) had higher frequency of hyperlipoproteinemia (mainly type IV) than those with apo E3/3 (25.8%). Furthermore, the middleaged subjects with apo E3/2 had significantly higher levels of plasma TG, VLDL-TG and apo E, and significantly lower levels of plasma high density lipoprotein-cholesterol than those with apo E3/3. These results indicate that apo E phenotype E3/2 and E4/3 are associated with lipid abnormalities even in young subjects, which may be caused by impaired functions of apo E2 and E4. apolipoprotein E phenotypes ; plasma lipids ; hyperlipoproteinemia ; young subjects ; middle-aged subjects Apolipoprotein (apo) E, one of the major protein constituents in very low density lipoprotein (VLDL ), has been thought to play an important role in lipoprotein metabolism. Apo E exhibits polymorphism that is genetically determined. The genetic and biochemical studies by Utermann et al. (1977) , and by Zannis and Breslow (1981) have revealed that three different apo E alleles, € 4, € 3 and E2, at a single genetic locus, produce major apo E isoproteins, E4. E3 and E2. Six apo E phenotypes, i.e. E2/2, E3/2, E3/3, E4/2, E4/3 and E4/4 have been recognized based on the genetic models of three alleles (Zannis et al. 1982). Apo E3/3 is the commonest phenotype in the population.
Apo E phenotypes are well known to be associated with hyperlipoproteinemia and atherosclerosis. The apo E2/2 is found frequently in type III hyperlipoproteinemia which is associated with premature atherosclerosis (Utermann et al. 1975) . Even heterozygote, apo E3/2 has been reported to be associated with dyslipoproteinemia, i.e., an increase of plasma triglyceride (TG), cholesterol-rich VLDL and apo E, and a decrease of plasma low density lipoprotein-cholesterol (LDL-C) (Utermann et al. 1979; Havel 1982) . Furthermore, an increased frequency of apo E4/4, E4/3 and E4/2 in patients with type V hyperlipoproteinemia (Ghiselli et al. 1982) or in survivors of myocardial infarction (Cumming and Robertson 1984) has been reported as well. Thus, apo E2 and E4 seem to exert certain effects on plasma lipid and lipoprotein levels. However, the relationship between apo E phenotypes and plasma lipid and lipoprotein levels is not yet fully understood. In addition, it is not until middle-age that hyperlipoproteinemia, with an exception of a portion of familial hyperlipoproteinemia, is expressed. At present a little information concerning the effects of apo E phenotypes on plasma lipids in young subjects is available.
The aim of this study is, therefore, to investigate the effects of apo E phenotypes on plasma lipid, lipoprotein and apo E levels in young and middleaged subjects.
SUBJECTS AND METHODS

Subjects
Forty-five young subjects aged 18-25 years (36 males and 9 females, 21 ± 1 years, mean±S.E.) were selected randomly from students of our medical school. 132 middle-aged subjects aged 35-64 years (111 males and 21 females, 49+2 years) were selected randomly from those who were hospitalized for two days to undergo complete physical examination although they had no subjective symptoms. Laboratory and clinical data are shown in Tables 1 and 2 . Subjects with obesity (relative weight_> 120%) or glucose intolerance were excluded, but no exclusion was made on the basis of plasma lipid levels. All of them had Measurement of plasma lipid, lipoprotein and apo E Blood samples were collected in mg/ml EDTA from an antecubital vein after an approximately 15-hr overnight fast and plasma was separated by centrifugation. Plasma TO (Bucolo and David 1973) and total cholesterol (TC) (Allain et al. 1974) were measured enzymatically. Plasma high density lipoprotein-cholesterol (HDL-C) was measured by a 1u1-scale ultracentrifugal method as reported previously (Eto et al. 1984) . VLDL was isolated by the method of Havel et al. (1955) . Plasma samples were centrifuged in a Hitachi Model 65P-7 ultracentrifuge (Hitachi Koki Co., Tokyo) using an RP-65T rotor (Hitachi Koki Co.) at 43,000 r.p.m. and 10°C for 20 hr. The top VLDL fraction was collected for the determination of TC and TG. TG (VLDL-TG) and TC (VLDL-C) were measured enzymatically as described above. Plasma LDL-C was calculated by subtracting VLDL-C and HDL-C from TC. Plasma apo E levels were determined by the single radial immunodiffusion method using Apo E plate (Daiichi Chemical Co., Tokyo). The intraassay and interassay coefficients of variation were below 5% for apo E.
Determination of types of hyperlipoproteinemia
Hyperlipoproteinemia in this study was classified into type ha (TG < 150 and LDL-C >_ 165 mg/ 100 ml), type IIb (TG >_ 150 and LDL-C _> 165 mg/ 100 ml) and type IV (TG >_ 150 and LDL-C < 165 mg 100 ml), respectively according to the plasma TG and LDL-C levels. No chylomicron band was detected in any subject by an agarose gel electrophoresis of plasma lipoprotein (Noble 1968) . No /3-VLDL was detected by polyacrylamide disc gel electrophoresis (Narayan 1966 ).
Determination of apo E phenotypes
The isolated VLDL fraction was delipidated, with an acetone-ethanol mixture (1;1, V/ V) and then with diethyl ether at -20°C (Warnick et al. 1979) . After drying, apo VLDL was solubilized in 80-1501ul of 0.01 mol/l Tris-HC1 buffer, pH 8.6, with 8 mol/l urea and 0.01 mol/l dithiotreitol just before electrophoresis. Apo E phenotypes were then determined by a rapid flat gel isoelectric focusing method as reported previously (Eto et al. 1985) ( Fig. 1) . Comparison of frequency of hyperlipoproteinemia between different apo E phenotypes was made by x 2 test.
RESULTS
As shown in Tables 1 and 2 , there was no difference among various apo E phenotypes of the young and middle-aged subjects as regards age and body weight. The frequency of apo E phenotype in the young or middle-aged subjects in the present study (Tables 1 and 2 ) was almost similar to that in the entire Japanese population as reorted previously (Eto et al. 1985) . Neither phenotype apo E2/2 nor E4/4 was found in the young subjects. Table 3 shows plasma lipid, lipoprotein and apo E levels for different apo E phenotype groups of the young subjects. Plasma TG, VLDL-TG and VLDL-C levels were significantly higher in apo E3/2 and E4/3 groups of the young subjects than in apo E3/3 group. Plasma TC and LDL-C levels were somewhat higher in apo E4/3 group than in apo E3/3 group. Plasma apo E levels and VLDL-C/ VLDL-TG ratio were somewhat higher in apo E3/2 group than in apo E3/3 and E4/3 groups. But it was not statistically significant. Table 4 shows the breakdown and frequency of hyperlipoproteinemia for different apo E phenotype groups of the middle-aged subjects. Only the results of apo E phenotypes E3/2, E3/3 and E4/3 were compared because the number of subjects with apo E2/2, E4/2 and E4/4 was very small. Hyperlipoproteinemia observed in this study consisted mainly of type IV. The frequency of hyperlipoproteinemia was highest in apo E3/2 group (54.5%), followed by apo E4/3 for different apo E phenotype groups of young subjects Breakdown and frequency of phenotype groups o middle-aged hyperlipoproteinemia subjects in different apo E (39.1%) and apo E3/3 (25.8%) groups in the order described. A significant (x2 _ 3.97, p <0.05) difference in the frequency of hyperlipoproteinemia was observed between apo E3/2 and E3/3 groups. Table 5 shows plasma lipid, lipoprotein and apo E levels for different apo E phenotype groups of the middle-aged subjects. Plasma TO, VLDL-TG and apo E levels were significantly higher in apo E3/2 group than in apo E3/3 group. In contrast, plasma HDL-C levels were significantly lower in apo E3/2 group than apo E3/3 group. Plasma VLDL-C levels and VLDL-C/VLDL-TG ratio tended to be higher, and plasma TC and LDL-C levels tended to be lower in apo E3/2 group than in apo E3/3 and E4/3 groups. Furthermore, plasma TO and VLDL-TG were slightly increased in apo E4/3 group as compared with those in apo E3/3 group. But it was not statistically significant.
Two subjects with apo E4/2 had higher levels of plasma TO, VLDL-TG, VLDL-C and apo E than those with apo E3/3 (Tables 3 and 5) .
DISCUSSION
In the present study the relationship between apo E phenotypes and the levels of plasma lipid, lipoprotein and apo E in young and middle-aged subjects was investigated.
Since age, body weight (Tables 1 and 2 ), amount of physical exercise and alcohol intake, and smoking habit (data not shown) were almost similar among the common three phenotype (apo E3/3, E3/2 and E4/3) groups of the young and middle-aged subjects in this study the effects of the above factors on plasma lipids can be presumably disregarded.
The young and middle-aged subjects with apo E3/2 showed an increase of plasma TO, VLDL-TG, VLDL-C, apo E and VLDL-C/VLDL-TG ratio. In addition, the middle-aged subjects with apo E3/2 showed a decrease of plasma TC, LDL-C and HDL-C. The frequency of hyperlipoproteinemia was higher in apo E3/2 than in apo E3/3 and E4/3. These lipid abnormalities observed in apo E3/2 can be explained by the data of Utermann et al. (1979) , Havel (1982) , Menzel et al. (1983) and Robertson and Cumming (1985) . They showed that subjects with apo E3/2 had dyslipopoteinemia which is similar to type III hyperlipoproteinemia, i.e. an increase of plasma TO, cholesterol-rich VLDL and apo E, and a decrease of plasma TC and LDL-C. It has been proposed that an abnormal lipoprotein receptor-binding activity of apo E2 may be responsible for the impaired catabolism of chylomicron and VLDL remnant (Weisgraber et al. 1982) , which leads to dyslipoproteinemia as described above even in the heterozygote, apo E3/ 2. Furthermore, apo E3/2 has been reported to exert dyslipoproteinemic and atherogenic effects, the magnitude of which is intermediate between apo E3/3 and E2/2 (Utermann et al. 1979) . The finding that apo E2 allele elevates the levels of plasma TG and VLDL, and lowers those of plasma TC and LDL-C, as recently reported by Sing and Davignon (1985) , may also support our data. However, the reason for the unchanged levels of plasma TC and LDL-C in young subjects with apo E3/2 is not clear. Hyperlipoproteinemia observed in the middle-aged subjects with apo E3/2 in this study was classified as type IV according to the above criteria, although apo E3/2 is usually associated with dyslipoproteinemia similar to type III. Our observation of higher frequency of type IV hyperlipoproteinemia in apo E3/2 suggests that apo E3/2 may be associated also with type IV hyperlipoproteinemia. In fact, Sing and Davignon (1985) have reported an enrichment of apo E2 allele in types IV and III.
On the other hand, the young subjects with apo E4/3 showed an increase of plasma TG, VLDL-TG and VLDL-C, and middle-aged subjects with apo E4/3 showed the increased frequency of hyperlipoproteinemia (mainly type IV), which was intermediate between apo E3/3 and E3/2. The mechanism by which these lipid abnormalities occur in apo E4/3 seems to differ from that in apo E3/2 , since for different apo E phenotype groups of middle-aged subjects a lipoprotein receptor-binding activity of apo E4 has been reported to be intact (Weisgraber et al. 1982) . In fact, we have found a difference in lipid abnormalities between apo E4/3 and E3/2. Ghiselli et al. (1982) have reported an increased frequency of apo E4 in type V hyperlipoproteinemia, i.e. an increase of chylomicron and VLDL. Gregg et al. (1982 ) have reported an abnormal metabolism of apo E4, suggesting that apo E4 presumably has an abnormal function which differs from that of apo E2, and that apo E4 exerts certain effects on TG-rich lipoprotein catabolism. Our result that apo E4/3 may be associated also with type IV hyperlipoproteinemia supports their findings concerning the abnormal function of apo E4. However, the effects of apo E4 on plasma lipids seems, at present, controversial since Stuyt et al. (1982) and Wardell et al. (1982) reported that apo E4 exerted no effects on plasma lipids. In addition, an elevating effect of apo E4 on plasma TC and LDL-C has been recently reported Cumming 1985, Sing and Davignon 1985) . In this study, the young subjects with apo E4/3 showed a slightly elevated levels of TC and LDL-C, whereas the middle-aged subjects with apo E4/3 showed unchanged levels of plasma IC and LDL-C. Further studies will be required to elucidate the effects of apo E4 on plasma TO and TC levels. In this connection it is to be noted that apo E4 is associated with increased risk of coronary heart disease (Cumming and Robertson 1984) . Based on the results described above, it is likely that the abnormal functions of apo E2 and E4 may be responsible for the occurrence of hyperlipoproteinemia in two subjects with apo E4/2 in this study although this mechanism seems complex (Eto et al. 1986) .
It is of considerable interest that lipid abnormalities exist in apo E3/2 and E4/3 even at a young age. This finding suggests that plasma TO and VLDL-lipid levels in young subjects are, at least in part, genetically controlled through apo E phenotypes. Our cross-sectional study in both young and middle-aged subjects indicated that the young subjects with apo E3/2 and E4/3 may, later in life, be susceptible to hyperlipoproteinemia. Providing that the above assumption is valid, such young subjects should exercise due precaution against hyperlipoproteinemia.
It is concluded that apo E phenotype E3/2 and E4/3 are associated with lipid abnormalities even in young subjects, which may be caused by impaired functions of apo E2 and E4. 
